Traumatic brain injury (TBI) is one of the most serious public health problems worldwide, leaving millions with lasting cognitive and physical disabilities. Despite decades of research, early diagnosis and effective treatment remain challenging. Now, researchers have explored a new frontier, theranostic nanomaterials, tiny engineered particles that can both diagnose and treat TBI, while addressing the limitations of traditional biosensing and therapy strategies.

Gynecological cancers remain a major threat to women's health, with traditional therapies often having limited effect and severe side effects. A new class of "“Magic bullets", known as Antibody-Drug Conjugates (ADCs), is now changing the game. With the first ADC for cervical cancer already approved and more in development for ovarian and uterine cancers, new hope is emerging for patients with recurrent disease. A literature review published in SCIENCE CHINA Life Sciences provides a comprehensive overview of ADCs, synthesizing existing evidence from ongoing clinical trials and preclinical studies in gynecological cancers. It examines the adverse reactions associated with ADCs and explores strategies to mitigate these adverse effects, thereby enhancing the efficacy of ADCs in treating gynecological malignancies.

Researchers propose a novel closed-loop system merging brain-computer interfaces and peripheral nerve stimulation to enable real-time, adaptive therapy for neuropsychiatric disorders like depression and ADHD. This approach dynamically tailors treatment to individual brain signals, overcoming limitations of one-size-fits-all methods. The technology promises precision neuromodulation, targeting specific neural circuits without invasive surgery.

Recently, the research team led by Professor Ling Shuai from the State Key Laboratory of Medicinal Chemical Biology at Nankai University has successfully activated the totipotency in mouse embryonic stem cells by overexpressing the key gene Hmgn3. Through mechanistic studies, the team discovered that Hmgn3 exerts its function by interacting with the Dux family genes. This study provides a brand-new strategy and model for research in early embryonic development and regenerative medicine.